Kit Components

The SUPPRELIN® LA implant is supplied in a sterile vial of saline within an amber plastic bag, which in turn is in a carton. The implant should be kept refrigerated (2-8º C/36-46º F) until the day of the procedure.

The kit comes equipped with the components recommended for the insertion and removal of the implant. The kit itself does not require refrigeration.

Next: SUPPRELIN® LA Key Steps

Indication

SUPPRELIN® LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP).

Important Safety Information

  • SUPPRELIN LA is contraindicated in women who are or may become pregnant, and in patients who are hypersensitive to GnRH or GnRH agonist analogs. Safety and effectiveness in pediatric patients under the age of 2 years has not been established.

  • SUPPRELIN LA, like other GnRH agonists, initially causes a transient increase in serum concentrations of estradiol in females and testosterone in both sexes during the first week of treatment, with worsening or onset of new symptoms during this period. Within 4 weeks of therapy, gonadal steroid suppression occurs and manifestations of puberty decrease.

  • Implant insertion and removal is a surgical procedure and should utilize aseptic technique. Careful adherence to the recommended insertion and removal procedures is recommended. On occasion, localizing and/or removal of implant products have been difficult and imaging techniques were used, including ultrasound, CT, or MRI (this implant is not radiopaque).

  • Rare events of spontaneous extrusion have been observed in clinical trials.

  • LH, FSH and estradiol or testosterone should be monitored at 1 month post implantation then every 6 months. Every 6-12 months, height and bone age should also be assessed.

  • In clinical trials, the most common adverse reactions involved the implant site and included bruising, pain, soreness, erythema and swelling.

Please see the accompanying full Prescribing Information.